The Holy Grail of Presbyopia Correction: IOL Technologies Today and Tomorrow to Meet Our Patients’ Needs | ASCRS
Satellite CME Programs

The Holy Grail of Presbyopia Correction: IOL Technologies Today and Tomorrow to Meet Our Patients’ Needs

Available On Demand Now

CME Activity Expired

This program took place live on Wednesday, January 27, 2021 and is now available in on-demand format for viewing only.

Presbyopia-correcting IOL technologies continue to expand, providing greater options and range of uncorrected vision for more patients. This program explores the growing portfolio of presbyopia-correcting IOLs, dives into the patient selection process for the various lens technologies, and addresses how to evaluate and manage the post-operative surprise patient. It is equally important to optimize the peri-operative process for the patient and the surgeon, and experts will review pearls, medications and digitalization of the cataract surgery journey.

ASCRS gratefully acknowledges the unrestricted educations grants received in support of this program from:

Johnson & Johnson

ASCRS gratefully acknowledges the unrestricted educational grants received in support of the 2020 ASCRS Virtual Annual Meeting and Bonus CME Enduring Activities from:

Alcon Vision, LLC
Bausch + Lomb
Carl Zeiss Meditec
EyePoint Pharmaceuticals, Inc.
Omeros Corporation

Program Chairs

Nicole Fram, MD

Elizabeth Yeu, MD


Shamik Bafna, MD

Thomas Kohnen, MD

Naveen Rao, MD

Continuing Medical Education (CME) Credits

Accreditation Statement

The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.

Designation Statement
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Educational Objectives

Upon completion of this program, participants should be able to:

  • Review the landscape of presbyopia-correcting IOLs available today and in the pipeline.
  • Address the patient selection process and identify strategies to meet the needs for presbyopia correction in today’s cataract surgery patient
  • Determine key preoperative diagnostics that will guide proper patient selection with appropriate IOLs
  • Review the evaluation process to manage the less-than-satisfied post-operative surgery patient and enhance overall outcomes.


Claim CME/CE Credits

Attendees will be able to evaluate this webinar electronically. At the conclusion of the program, attendees will be emailed a link to the program evaluation and credit claim. Please contact Janell John, ASCRS CME Coordinator, at with any questions on credit claims.

Notice About Off-Label Use Presentations

The webinar may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.

ADA/Special Accommodations

ASCRS fully complies with the legal requirements of the American with Disabilities Act (ADA) and the rules and regulations thereof. ASCRS also requires ADA compliance from its contracted vendors and facilities. Any participant in this educational program who requires special accommodations or services should contact a staff member.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.